AC220 + daunorubicin + cytarabine
Phase 1Completed 2 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Myeloid, Acute
Conditions
Leukemia, Myeloid, Acute
Trial Timeline
Oct 1, 2011 → Feb 1, 2015
NCT ID
NCT01390337About AC220 + daunorubicin + cytarabine
AC220 + daunorubicin + cytarabine is a phase 1 stage product being developed by Daiichi Sankyo for Leukemia, Myeloid, Acute. The current trial status is completed. This product is registered under clinical trial identifier NCT01390337. Target conditions include Leukemia, Myeloid, Acute.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Myeloid, Acute were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01390337 | Phase 1 | Completed |
Competing Products
20 competing products in Leukemia, Myeloid, Acute